Biosimilar

Anti-VEGF agents have transformed retinal disease management.

The FDA approved Idacio as a biosimilar to Humira, a TNF inhibitor with indications for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis.

In 2021, Humira, the blockbuster biologic that has for years been the highest grossing drug in the world, accomplished something that no drug had previously achieved when its global revenues topped $20 billion.

Cigna Pharmacy announced that it will add adalimumab biosimilars as “preferred products” at the same price level as the originator Humira on its commercial formularies, according to a company press release.

The FDA has approved Idacio as the eighth biosimilar to adalimumab, for all eligible indications of the reference product, clearing the way for its U.S. release in 2023 alongside a deluge of other Humira biosimilars.

The FDA has accepted an abbreviated biologics license application for a tocilizumab biosimilar candidate, according to a press release from Biogen.

The FDA approved the second interchangeable insulin glargine biosimilar, Rezvoglar, to improve glycemic control in adults and pediatric patients with diabetes, according to a drug information update from the agency.

PHILADELPHIA — Patients who switched from one infliximab biosimilar to another experienced comparable treatment retention rates, according to data presented at ACR Convergence 2022.

Supply chain disruptions have forced nearly two-thirds of rheumatologists to substitute medications for their patients, according to survey results published by Cardinal Health.

The American Gastroenterology Association recently spoke out about data that showed colonoscopy screening had a modest benefit in colorectal cancer.